Skip to main content

Antibody Mediated Rejection clinical trials at UCSF

1 research study open to eligible people

Antibody mediated rejection is when a transplanted kidney is attacked by the body's own immune system. UCSF is recruiting for a clinical trial testing clazakizumab, a treatment designed to stop this attack. The goal is to see if clazakizumab is effective and safe for kidney transplant recipients with chronic active antibody mediated rejection.

Showing trials for

Last updated: